Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$11 Mln
P/E Ratio
--
P/B Ratio
2.06
Industry P/E
--
Debt to Equity
--
ROE
-1.15 %
ROCE
-114.51 %
Div. Yield
0 %
Book Value
4.72
EPS
-7.15
CFO
$-92.05 Mln
EBITDA
$-92.91 Mln
Net Profit
$-100.81 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Phio Pharmaceuticals (PHIO)
| 10.00 | 53.49 | -22.35 | -67.74 | -72.60 | -60.11 | -70.33 |
|
BSE Sensex*
| 2.55 | 3.65 | 4.54 | 7.46 | 12.04 | 19.65 | 11.41 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Phio Pharmaceuticals (PHIO)
| -73.40 | -82.97 | -62.80 | -62.83 | -71.40 | -48.17 | -93.97 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 38.55 | 10,593.45 | 21.84 | 23.13 | |
| 306.35 | 8,570.17 | 22.78 | 66.44 | |
| 27.82 | 10,589.59 | -- | -28.77 | |
| 107.24 | 10,559.67 | 32.44 | 14.16 |
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death... protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. Address: 11 Apex Drive, Marlborough, MA, United States, 01752 Read more
President, CEO & Chairman
Mr. Robert J. Bitterman
President, CEO & Chairman
Mr. Robert J. Bitterman
Headquarters
Marlborough, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Phio Pharmaceuticals Corp (PHIO) stood at $ 6 Mln as on 31-Dec-24
The share price of Phio Pharmaceuticals Corp (PHIO) is $1.98 (NASDAQ) as of 29-Apr-2025 16:18 EDT. Phio Pharmaceuticals Corp (PHIO) has given a return of -72.6% in the last 3 years.
Phio Pharmaceuticals Corp (PHIO) has a market capitalisation of $ 11 Mln as on 28-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Phio Pharmaceuticals Corp (PHIO) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Phio Pharmaceuticals Corp (PHIO) and enter the required number of quantities and click on buy to purchase the shares of Phio Pharmaceuticals Corp (PHIO).
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts. Address: 11 Apex Drive, Marlborough, MA, United States, 01752
The CEO & director of Mr. Robert J. Bitterman. is Phio Pharmaceuticals Corp (PHIO), and CFO & Sr. VP is Mr. Robert J. Bitterman.
There is no promoter pledging in Phio Pharmaceuticals Corp (PHIO).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Phio Pharmaceuticals Corp. (PHIO) | Ratios |
|---|---|
|
Return on equity(%)
|
-114.83
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Phio Pharmaceuticals Corp (PHIO) was $0 Mln.
$-0.16
(
